Hemophilia Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025

The hemophilia therapeutics market share is expected to increase by USD 4.47 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 6.16%.

This hemophilia therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers hemophilia therapeutics market segmentation by type (hemophilia A, hemophilia B, and hemophilia C) and geography (North America, Europe, Asia, and ROW). The hemophilia therapeutics market report also offers information on several market vendors, including Baxter International Inc., Bayer AG, Biogen Inc., CHIESI Farmaceutici SpA, CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk AS, Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd. among others.

What will the Hemophilia Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Hemophilia Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Hemophilia Therapeutics Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The new drug approvals are notably driving the hemophilia therapeutics market growth, although factors such as cost-intensive and complex treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the hemophilia therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Hemophilia Therapeutics Market Driver

In the past years, bleeding episodes in patients with coagulation disorders such as hemophilia were treated with replacement therapy, whole blood and fresh frozen plasma, and specific factor concentrate as a replacement. Despite the availability of safe and effective replacement therapy, patients with hemophilia A and hemophilia B experience a high burden of treatment and breakthrough bleeding. Therefore, the development and approval of new therapeutics with high efficacy and the ability to overcome the above-mentioned challenges have become the priority for researchers. Several players in the market are focused on identifying novel strategies to treat hemophilia. Owing to this, the market has been witnessing the development and approval of therapeutics, which will drive market growth during the forecast period. 

Key Hemophilia Therapeutics Market Trend

Currently, most of the hemophilia therapeutics available in the market are short-acting, i.e., used only when the patient suffers from bleeding. Many hemophilia therapeutics also exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products. In order to mitigate these issues, technologies such as recombinant DNA, protein fusion, and PEGylation technologies are used for the production of new therapies with a longer lifespan and fewer immunogenic reactions. For instance, Biogen offers rFVIIIFc, a recombinant next-generation therapeutic product for hemophilia A therapy. It is the firm's leading product and is a truncated version of factor VIII, fused to the Fc domain of an antibody, which extends the half-life of the product in the bloodstream. This recombinant product is developed using Biogen's protein fusion technology. Thus, increased use of technologies for the development of innovative products is expected to drive the hemophilia therapeutics market during the forecast period.

Key Hemophilia Therapeutics Market Challenge

The treatment for hemophilia can turn out to be very complex if proper guidelines are not followed during the preparation of therapeutics and also during consumption. Current treatments pose certain limitations, such as the risk of infection, treatment resistance, poor compliance, and adverse effects. The introduction of novel therapeutics and their successful scale-up have resulted in the reduction of morbidity and mortality associated with hemophilia. These therapeutics have proven effective and have been well-tolerated in the past years to become the standard in hemophilia-related healthcare. However, these therapeutics are expensive, which becomes a financial burden for individuals living with blood disorders and receiving therapies. Therefore, the high treatment cost may adversely affect patient adherence to treatment and become a challenge for market growth during the forecast period.

This hemophilia therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

The growth in the global healthcare market will be driven by factors such as increasing life expectancy, improving access to better healthcare in emerging economies, and increasing cases of chronic conditions. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the hemophilia therapeutics market during the forecast period.

Who are the Major Hemophilia Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Baxter International Inc.
• Bayer AG
• Biogen Inc.
• CHIESI Farmaceutici SpA
• CSL Ltd.
• F. Hoffmann-La Roche Ltd.
• Novo Nordisk AS
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

 

This statistical study of the hemophilia therapeutics market encompasses successful business strategies deployed by the key vendors. The hemophilia therapeutics market is fragmented and the vendors are deploying growth strategies such as strategic alliances to compete in the market.

Product Insights and News

• Baxter International Inc - The company offers BAX 855 hemophilia therapeutics for the treatment of hemophilia A.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The hemophilia therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Hemophilia Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the hemophilia therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the healthcare market includes the following core components:

• Research and development (R&D) and drug discovery
• Integration and product development
• Manufacturing
• Outbound logistics
• Marketing and sales
• Support services
• Innovation

The report has further elucidated on other innovative approaches being followed by vendors to ensure a sustainable market presence.

 

Which are the Key Regions for Hemophilia Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for hemophilia therapeutics in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.

The presence of a high patient base will facilitate the hemophilia therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The rise in the incidence of COVID-19 in various countries in North America influenced governments to introduce emergency legislation, which included restrictions on several business activities. A few essential industries, such as pharmaceutical industries, were allowed to operate at the usual utilization rates. The manufacturing plants of pharmaceutical industries in the region were operating to enable the supply of key medicines, including hemophilia therapeutics, by managing workforce safety to cater to the growing demand from consumers. However, as most pharmaceutical companies focused on developing COVID-19 vaccines and manufacturing other therapeutics to support the medical crisis associated with COVID-19, the production volume of therapeutics for other therapeutic areas was lower than the actual to a certain extent during the first few months of 2020. This, in turn, resulted in slow growth of the hemophilia therapeutics market in North America in 2020. 

What are the Revenue-generating Type Segments in the Hemophilia Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The hemophilia therapeutics market share growth by the hemophilia A segment will be significant during the forecast period. Hemophilia A, which is caused due to the deficiency of clotting factor VIII, is more prevalent than hemophilia B and von Willebrand disease. The hemophilia A therapeutics market is expected to grow due to the shift in consumer interests to prophylactic therapy and new product launches during the forecast period. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the hemophilia therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Hemophilia Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 6.16%
Market growth 2021-2025	$ 4.47 billion
Market structure	Fragmented
YoY growth (%)	5.85
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 41%
Key consumer countries	US, UK, Germany, China, and Canada
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Alnylam Pharmaceuticals Inc., Amarna Holding B.V., Asklepios BioPharmaceutical Inc., Baxter International Inc., Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc., Catalyst Biosciences, Inc., CHIESI Farmaceutici SpA, CSL Ltd., F. Hoffmann-La Roche Ltd., Ferring B.V., Grifols SA, Medexus Pharmaceuticals Inc., Novo Nordisk AS, Octapharma AG, OPKO Health Inc., Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Hemophilia Therapeutics Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive hemophilia therapeutics market growth during the next five years
• Precise estimation of the hemophilia therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the hemophilia therapeutics industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of hemophilia therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch